REG - Arecor Therapeutics - Arecor Granted Key U.S Patent

Arecor TherapeuticsAnnouncement

26/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230426:nRSZ4505Xa&default-theme=true

RNS Number : 4505X  Arecor Therapeutics PLC  26 April 2023

Arecor Therapeutics plc

("Arecor" or the "Group")

 

US PATENT GRANTED PROTECTING PROPRIETARY FORMULATIONS OF MONOCLONAL ANTIBODIES

 

-      Endorses potential of proprietary Arestat™ platform technology
to invent novel, enhanced therapeutics in $210 billion monoclonal antibody
market

-      Further strengthens Group's extensive patent portfolio

 

Cambridge, UK, 26 April 2023: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
is pleased to announce that the United States Patent and Trademark Office has
granted a patent (US11608357) protecting a novel formulation platform that
enables the development of enhanced monoclonal antibodies.

 

Monoclonal antibodies represent a key segment of the biopharmaceuticals
market, valued at $210 billion in 2022 and are projected to see a compound
annual growth rate (CAGR) of 11.04% from 2023 to 2030(1).

 

There has been a strong drive towards patient-centricity in the
biopharmaceutical industry, particularly in the development of convenient
dosage forms. However, achieving such desirable dosage forms is often hampered
by insufficient stability or high viscosity of monoclonal antibodies when
formulated using conventional formulation approaches. To address this problem
Arecor has developed a number of highly innovative, proprietary formulation
platforms enabling superior stability of monoclonal antibodies under various
stress conditions. This US patent protects one of these proprietary
formulation platforms within the Group's broader Arestat™ technology.

 

Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: "Whilst a number
of novel therapeutic modalities are being developed, such as complex
engineered protein constructs or mRNA therapies, monoclonal antibodies
continue to dominate the biopharmaceutical field. Safety and efficacy are
obviously the key criteria for any new product, but the increasing focus on
patient-centricity and improved convenience of delivery often requires
superior product stability which is often difficult to achieve using
conventional approaches. Our highly innovative formulation technology
addresses these challenges and, when applied, we are able to develop enhanced
novel pharmaceutical products, both for our growing partnerships with Pharma
companies and in our proprietary pipeline. This US patent is a very important
addition to our IP portfolio, protecting a formulation design space that
enables monoclonal antibodies with superior stability."

 

Arecor leverages its Arestat™ technology in partnerships with leading
pharmaceutical and biotechnology companies to deliver enhanced products under
a technology licensing model, as well as developing an internal portfolio of
proprietary products in diabetes and other indications.  As part of this
strategy Arecor continues to invest in a strong patent portfolio to protect
the Arestat™ platform, currently comprising 38 patent families and >75
granted patents.

 

References

1.
https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market
(https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market)

 

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

Notes to Editors

 

About Arestat™

Arecor's Arestat™ technology enables superior product profiles across a
broad range of therapies, including various types of biopharmaceuticals and
specialty hospital products. In addition to its internal portfolio of superior
proprietary products in diabetes and other indications, Arecor leverages the
Arestat™ technology in partnerships with leading pharmaceutical and
biotechnology companies to deliver enhanced products under a technology
licensing model.

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAELSAFDDEAA